At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
UNCY Unicycive Therapeutics, Inc.
Closed 02-02 16:00:00 EST
6.45
+0.48
+8.04%
盘后6.49
+0.04+0.62%
19:55 EST
High6.55Low5.89Vol586.53K
Open5.97D1 Closing5.97Amplitude11.05%
Mkt Cap138.62MTradable Cap83.90MTotal Shares21.49M
T/O3.71MT/O Rate4.51%Tradable Shares13.01M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Unicycive Therapeutics Showcases Pipeline Advancements in Kidney Disease Treatments
Reuters  ·  01-31
Unicycive Therapeutics Showcases Pipeline Advancements in Kidney Disease Treatments
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Unicycive Therapeutics (UNCY)
TIPRANKS  ·  01-30
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Unicycive Therapeutics (UNCY)
De-Risked Regulatory Path and Commercial Readiness Underpin Buy Rating on Unicycive and Lead Asset OLC
TIPRANKS  ·  01-30
De-Risked Regulatory Path and Commercial Readiness Underpin Buy Rating on Unicycive and Lead Asset OLC
BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, Summit, Lockheed Martin
Reuters  ·  01-29
BUZZ-U.S. STOCKS ON THE MOVE-Blackstone, Summit, Lockheed Martin
Unicycive Therapeutics Inc - FDA Assigns Pdufa Target Date of June 29, 2026
THOMSON REUTERS  ·  01-29
Unicycive Therapeutics Inc - FDA Assigns Pdufa Target Date of June 29, 2026
Update - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (Olc) New Drug Application (Nda) Resubmission
THOMSON REUTERS  ·  01-29
Update - Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (Olc) New Drug Application (Nda) Resubmission
BUZZ-Unicycive rises as FDA accepts resubmitted filing for kidney drug
Reuters  ·  01-29
BUZZ-Unicycive rises as FDA accepts resubmitted filing for kidney drug
Unicycive Therapeutics Inc - Pdufa Target Action Date Set for June 27, 2026
THOMSON REUTERS  ·  01-29
Unicycive Therapeutics Inc - Pdufa Target Action Date Set for June 27, 2026
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
GlobeNewswire  ·  01-29
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission
Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and OLC Launch Plans in New Presentation
Reuters  ·  01-08
Unicycive Therapeutics Showcases Kidney Disease Drug Pipeline and OLC Launch Plans in New Presentation
Unicycive Resubmits NDA for Oxylanthanum Carbonate to FDA
Reuters  ·  2025-12-29
Unicycive Resubmits NDA for Oxylanthanum Carbonate to FDA
Unicycive Therapeutics Inc - Nda Submission Review Expected Within 6 Months per Prescription Drug User Fee Act
THOMSON REUTERS  ·  2025-12-29
Unicycive Therapeutics Inc - Nda Submission Review Expected Within 6 Months per Prescription Drug User Fee Act
Unicycive Therapeutics Inc - Nda Resubmitted After Vendor Resolves FDA Deficiencies
THOMSON REUTERS  ·  2025-12-29
Unicycive Therapeutics Inc - Nda Resubmitted After Vendor Resolves FDA Deficiencies
Unicycive Therapeutics Announces Resubmission of New Drug Application (Nda) for Oxylanthanum Carbonate (Olc)
THOMSON REUTERS  ·  2025-12-29
Unicycive Therapeutics Announces Resubmission of New Drug Application (Nda) for Oxylanthanum Carbonate (Olc)
Unicycive Therapeutics unveils new kidney disease treatment pipeline in latest corporate presentation
Reuters  ·  2025-12-03
Unicycive Therapeutics unveils new kidney disease treatment pipeline in latest corporate presentation
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
GlobeNewswire  ·  2025-11-25
Unicycive Therapeutics to Participate in Upcoming Investor Events in December
Unicycive Therapeutics: Buy Rating Backed by Promising OLC Progress and Strategic Market Positioning
TIPRANKS  ·  2025-11-16
Unicycive Therapeutics: Buy Rating Backed by Promising OLC Progress and Strategic Market Positioning
Unicycive Therapeutics Doubles Stock Sale Agreement
TIPRANKS  ·  2025-11-15
Unicycive Therapeutics Doubles Stock Sale Agreement
BRIEF-Unicycive Therapeutics Increases ATM Offering To $100 Million - SEC Filing
Reuters  ·  2025-11-15
BRIEF-Unicycive Therapeutics Increases ATM Offering To $100 Million - SEC Filing
Unicycive Therapeutics Inc - Increases Atm Offering to $100 Mln - SEC Filing
THOMSON REUTERS  ·  2025-11-15
Unicycive Therapeutics Inc - Increases Atm Offering to $100 Mln - SEC Filing

Introduction

Company Name.
Unicycive Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
Issue price:
--